RPV-LA Maintenance Dose — Competitive Intelligence Brief

RPV-LA Maintenance Dose (RPV-LA Maintenance Dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Disease.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV-1 reverse transcriptase Infectious Disease Small molecule

Target snapshot

RPV-LA Maintenance Dose (RPV-LA Maintenance Dose) — National Institute of Allergy and Infectious Diseases (NIAID). RPV-LA Maintenance Dose is a long-acting formulation of rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of HIV-1.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RPV-LA Maintenance Dose TARGET	RPV-LA Maintenance Dose	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Etravirine (ETR)	Etravirine (ETR)	ViiV Healthcare	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Doravirine (DOR)	Doravirine (DOR)	Walter K. Kraft	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Oral Tablet	Emtricitabine / Tenofovir Disoproxil Oral Tablet	University of Chicago	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class